Evaluation of the effect of vitamin D before percutaneous coronary intervention in the prevention of cardiovascular complications

Evaluation of the effect of loading dose of vitamin D before percutaneous coronary intervention in patients with unstable angina in reducing Major adverse cardiovascular events

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210228050528N1

Enrollment

Registered

2021-10-22

Start date

2021-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Major adverse cardiovascular events. Condition 2: Precutaneous coronary intervention. Condition 3: Unstable angina. Abnormal result of cardiovascular function study, unspecified Presence of coronary angioplasty implant and graft Atherosclerotic heart disease of native coronary artery with unstable angina pectoris

Interventions

Intervention 1: Intervention group: A group that, in addition to routine pre-PCI medications, is treated with 300,000 units of oral vitamin D (six 50,000 units of vitamin D tablets produced by Zahravi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with unstable angina who are candidates for PCI Patients with deficient serum levels of vitamin D

Exclusion criteria

Exclusion criteria: Previous history of myocardial infarction Previous history of revascularization therapy interventions Patients with a previous history of CABG Patients with failed PCI Simultaneous involvement of valvular disorders Take vitamin D, calcium or omega-3 supplements in the last 3 months Patients with hypercalcemia, nephrolithiasis, sarcoidosis, malabsorption syndromes Chronic underlying diseases such as liver, kidney or rheumatic disorders Pregnancy and lactation Having malignancies History of receiving corticosteroids or immunosuppressants in the last 6 months

Design outcomes

Primary

Measure	Time frame
Number of myocardial infarction cases. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.;Number of revascularization cases in re hospitalization. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.	—

Secondary

Measure	Time frame
Readmission rate. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.;Mortality rate. Timepoint: 3 and 6 months later. Method of measurement: In-person and telephone follow-up.;Cardiac function. Timepoint: 3 and 6 months later. Method of measurement: In-person follow-up.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Shahbazzadeh

Zanjan University of Medical Sciences

amirshahbazzadeh@yahoo.com+98 21 6653 5168

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026